Johnson & Johnson Stock News

Johnson & Johnson owes shareholders of Auris Health $1 billion in damages for breaching a 2019 agreement to acquire the private developer of robotics, a Delaware judge ruled on Wednesday.

Verizon offers a high-yielding and steadily rising dividend. Johnson & Johnson pays a very healthy dividend.

Johnson & Johnson is a remarkably consistent business. A fortress-like balance sheet all but guarantees the dividend's safety.

In addition to profiting from ordinary trading activities, the stock market offers opportunities for investors seeking passive income through dividend payouts.

If you are a Johnson & Johnson investor and have been enjoying the stock's steady dividends, it may be time to look elsewhere. As of this moment, we find DaVita - a healthcare company focused on kidney dialysis services - and Duke Energy - an electric and natural gas utility company based in North Carolina - as more attractive buys than Johnson & Johnson.

Marks first FDA submission for nipocalimab, an investigational treatment that binds with high affinity and specificity to block FcRn and reduce levels of autoantibodies  Filing based on the Phase 3 Vivacity-MG3 program, the first-and-only study results in the class demonstrating sustained disease control over 24 weeks in antibody positive adult patients: anti-AChR+, anti-MuSK+, anti-LRP4+ SPRIN...

In this article, I will present you with two high dividend yield companies that, I believe, are presently attractive, given their current Valuation, financial robustness, and leading competitive position. Both companies pay an attractive Dividend Yield [FWD] of 3.11% and 7.01%, and have the potential for dividend growth. While I suggest overweighting one company (with an allocation limit of 5%)...

Four RYBREVANT® (amivantamab-vmjw) studies feature compelling new findings in lung and colorectal cancers New TAR-200 data reveal the potential of organ-sparing therapy for the treatment of bladder cancer RARITAN, N.J. , Aug. 27, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that 11 oral presentations from the Company's industry-leading solid tumor portfolio and pipeline wi...